Tasadenoturev - DNAtrix

Drug Profile

Tasadenoturev - DNAtrix

Alternative Names: Ad-delta24-RGD; Ad-DNX 2401; Ad5-Delta 24RGD; Ad5-delta24-RGD; Adenovirus DNX 2401; Adenovirus-5 delta 24 RGD; Delta 24 RGD 4C; Delta-24-RGD; DNX 2401; IE-CRAd; RGD-delta24; Tasadenoturev; VLI-01A

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DNAtrix; University of Texas M. D. Anderson Cancer Center
  • Developer Clinica Universidad de Navarra; DNAtrix; Merck & Co; University of Alabama Comprehensive Cancer Center
  • Class Cancer vaccines; DNA vaccines; Oncolytic viruses
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Glioma
  • No development reported Ovarian cancer

Most Recent Events

  • 02 Jun 2017 Efficacy and safety data from the phase Ib TARGET-I trial in Glioblstoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 10 Mar 2017 Phase-II clinical trials in Glioblastoma (Combination therapy, Recurrent) in Canada (Intratumoural) (NCT02798406)
  • 03 Nov 2016 Phase-I clinical trials in Glioma (Newly diagnosed, In children, In adolescents, First-line therapy) in Spain (Intratumoural) (EudraCT2016-001577-33)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top